Bristol Myers Squibb Company $BMY Shares Purchased by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 13.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 103,117 shares of the biopharmaceutical company’s stock after buying an additional 11,902 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Bristol Myers Squibb were worth $6,254,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Bristol Myers Squibb during the first quarter worth $552,000. MASTERINVEST Kapitalanlage GmbH raised its stake in shares of Bristol Myers Squibb by 22.6% during the 1st quarter. MASTERINVEST Kapitalanlage GmbH now owns 9,097 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 1,677 shares during the last quarter. Ethos Financial Group LLC acquired a new position in shares of Bristol Myers Squibb during the 1st quarter worth $211,000. Opinicus Capital Inc. boosted its position in shares of Bristol Myers Squibb by 9.8% in the 1st quarter. Opinicus Capital Inc. now owns 12,850 shares of the biopharmaceutical company’s stock worth $779,000 after buying an additional 1,148 shares in the last quarter. Finally, Sanctuary Advisors LLC grew its stake in Bristol Myers Squibb by 5.7% in the 1st quarter. Sanctuary Advisors LLC now owns 358,571 shares of the biopharmaceutical company’s stock valued at $21,747,000 after acquiring an additional 19,316 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, a meaningful regulatory step that supports the company’s oncology pipeline and future revenue potential. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusually heavy call option buying suggested traders were positioning for further upside in BMY, with call volume well above normal levels.
• Positive Sentiment: Recent coverage highlighted Bristol Myers Squibb as a strong value stock and noted that its earnings surprise history could support another potential beat in the next quarterly report. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: BMY continued to attract investor attention and broad market discussion, which can amplify trading interest even without a specific new catalyst. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Wells Fargo reportedly assigned a Hold rating, and one market note said the stock underperformed peers earlier in the week, which may have tempered some enthusiasm. Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors

Bristol Myers Squibb Trading Up 3.0%

Shares of BMY stock opened at $60.47 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm’s 50 day moving average price is $56.93 and its two-hundred day moving average price is $57.76. The stock has a market cap of $123.48 billion, a price-to-earnings ratio of 16.99, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the prior year, the business earned $1.80 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.34 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Analyst Ratings Changes

BMY has been the subject of a number of research reports. Cantor Fitzgerald restated a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Bank of America reduced their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Guggenheim reiterated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $61.25.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.